Shao Lee Lin
Founder en ACELYRIN, INC. .
Fortuna: 23 M $ al 31/03/2024
Perfil
Shao Lee Lin is the founder and CEO of ACELYRIN, Inc. founded in 2020.
Currently, Dr. Lin holds two director positions at Surrozen Operating, Inc. and Surrozen, Inc. respectively.
Dr. Lin has held several director and VP positions at Principia Biopharma, Inc., Third Harmonic Bio, Inc., Gilead Sciences, Inc., AbbVie, Inc., and Horizon Therapeutics Plc.
Dr. Lin was also a trustee at Lake Forest College from 2018 to 2020.
Dr. Lin received an undergraduate degree from Rice University and a doctorate from The Johns Hopkins University School of Medicine.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
ACELYRIN, INC.
3.55% | 01/04/2024 | 3 452 329 ( 3.55% ) | 23 M $ | 31/03/2024 |
THIRD HARMONIC BIO, INC.
-.--% | 26/10/2022 | 0 ( -.--% ) | - $ | 31/03/2024 |
Cargos activos de Shao Lee Lin
Empresas | Cargo | Inicio |
---|---|---|
ACELYRIN, INC. | Founder | 27/07/2020 |
SURROZEN, INC. | Director/Board Member | 01/01/2021 |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Director/Board Member | 02/02/2021 |
Antiguos cargos conocidos de Shao Lee Lin.
Empresas | Cargo | Fin |
---|---|---|
THIRD HARMONIC BIO, INC. | Director/Board Member | 17/01/2023 |
PRINCIPIA BIOPHARMA INC. | Director/Board Member | 28/09/2020 |
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Chief Tech/Sci/R&D Officer | 23/01/2020 |
Lake Forest College | Director/Board Member | 01/01/2020 |
ABBVIE INC. | Corporate Officer/Principal | 01/12/2017 |
Formación de Shao Lee Lin.
Rice University | Undergraduate Degree |
The Johns Hopkins University School of Medicine | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 5 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
ABBVIE INC. | Health Technology |
THIRD HARMONIC BIO, INC. | Health Technology |
ACELYRIN, INC. | Health Technology |
SURROZEN, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Principia Biopharma, Inc.
Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
Horizon Therapeutics Plc
Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Shao Lee Lin